← Human Trials & Peer-Reviewed Studies
Effects of Acupuncture Treatment on Fibromyalgia Symptoms, Serotonin, and Substance P Levels: A Randomized Sham and Placebo-Controlled Clinical Trial
Plain-language guide to PMID 29220534 (2018): randomized controlled trial study of Substance P.
Key Facts
- PMID
- 29220534
- Journal
- Pain medicine (Malden, Mass.)
- Year
- 2018
- Study type
- Randomized Controlled Trial
- Authors
- Karatay S et al. (5 authors)
- DOI
- 10.1093/pm/pnx263
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Substance P.
The aim of this study was to evaluate the effects of acupuncture treatment on serum levels of serotonin and substance P (SP) as well as on clinical parameters in patients with fibromyalgia (FM).
Who Took Part
PubMed indexes the participants as young adults, adults and middle-aged adults, women only.
Seventy-five women with FM were randomized into one of three kinds of acupuncture treatment: real acupuncture group (AcG), sham acupuncture group (ShG), and simulated acupuncture group (SiG).
Treatments were applied semiweekly for four weeks.
How the Study Was Run
The design is described as randomized.
Random assignment meant chance, not the researchers, decided who got Substance P and who got the comparison, which limits bias.
A time span of four weeks appears in the methods.
This is a randomized controlled clinical trial.
The serum levels of serotonin and SP were evaluated before and after the eight sessions.
Patients were clinically assessed by visual analog scale (VAS), the number of tender points (NTP), Fibromyalgia Impact Questionnaire (FIQ), Beck Depression Inventory (BDI), and Nottingham Health Profile (NHP) at baseline, after the last treatment, and one and three months after completion of all treatments.
What Was Measured
The subject headings attached to it are Acupuncture Therapy, Fibromyalgia, Pain Management, Pain Measurement, Serotonin and Substance P.
What This Means in Plain Language
The paper is a randomized study of Substance P over four weeks.
Its findings take up roughly 10 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2018 (Pain medicine (Malden, Mass.)), a journal based in England.
More context: the Substance P compound page, all human trials.
Our Notes on the Compound
Substance P: An 11-amino-acid neuropeptide involved in pain signaling and inflammation; given in research studies.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.